.
To summarize, it seems unlikely that a compound will ever be produced which has a better response rate than those hormones or antihormones which are used at present. Almost certainly in any population there is a fixed number of tumours which are hormone-sensitive. No alteration of the androgen or cestrogen molecule can produce a substance which will affect those tumours which are hormoneinsensitive. Side-effects may be overcome but the response rate will remain the same.
Ablative Therapy Here again a situation of status quo has been reached. A proportion of tumours can be affected by removing the major sources of endogenous hormone production -the ovaries, the adrenals, or the pituitary. In the case of oopherectomy a further remission may be obtained by subsequent adrenalectomy or hypophysectomy, but hypophysectomy is seldom of value after an unsuccessful adrenalectomy and vice versa. Hypophysectomy has the highest response rate of all endocrine measures for the treatment of the advanced disease (Hayward et al. 1970) , probably because all sources of hormone production are stopped or diminished including that of the pituitary protein hormones.
Further development in this field must rely on the discovery of simpler ways of ablating the endocrine glands. At present the pituitary must be removed either by the transfrontal or the transsphenoidal route, but the operations have considerable morbidity in inexperienced hands. For a while the use of radioactive yttrium looked promising but it has now been shown to be less effective than surgical ablative procedures (Roberts 1970). Moreover, destruction of the pituitary by external irradiation is difficult, and needs very specialized and bulky equipment. A 'medical' hypophysectomy or adrenalectomy in which drugs are used to stop endocrine secretion is possible, and some preliminary work has been done using aminoglutethamide as an agent to abolish adrenal secretion (Griffiths et al. 1973 (Atkins et al. 1968 ).
More recently the measurement of cestrogen receptor sites in the tumour has become possible and preliminary work indicates that the estimations can be used to identify women who stand a good chance of responding to hormone administration or to ablative procedures (Jensen et al. 1971 ). This test, possibly used together with an assessment of the endocrine environment, may facilitate much more accurate prediction.
Probably it is in this field of prediction that most developments will be made in the future. At present most hormone therapies for advanced breast cancer are given on an empirical basis. The decision on the efficacy of a treatment is made usually by trying it in practice. With the development of more sophisticated assays, both of endocrine status and of the tumour's potential response, accurate assessment should be possible. Eventually, indications for the various treatments currently in use should be recognized, and it will be possible to find out whether or not a tumour is responsive and to which hormone or combination of hormones it will react. Only then will a precise and optimal regime of treatment be able to be devised for each patient.
Dr Philip Peacock (Rustington, retired): Sir George
Beatson was a Manxman and we first met in Glasgow in 1928. Beatson's ideas emanated from the observation that lactation was prolonged in cattle after castration. The first patient with advanced mammary cancer on whom he carried out the operation of oophorectomy, in 1896, survived 4 years.
Dr Basil A Stoll (St Thomas's Hospital, London): Prolactin has been shown to increase the mitotic activity of experimental mammary cancer, and it was hoped that the separation of prolactin from human growth hormone would greatly increase knowledge of the mechanisms of hormonal therapy in breast cancer.
However, although prolactin has been isolated and assayed, no great advances have been achieved so far. Both 2-a-bromoergocryptine and levodopa, which reduce prolactin levels, should have a beneficial effect on breast cancer, but this has not been my experience.
On the other hand, pituitary stalk section increases the level of prolactin enormously, yet in some patients milk has been expressed from one breast while the tumour in the other breast has regressed in size.
Furthermore, we were surprised when a group of workers in Belgium showed that administration of cestrogens at high dosage in fact increased the level of prolactin rather than decreased it. The place of prolactin in breast cancer is still uncertain.
We 
